Low-density granulocyte-driven NET formation is associated with poor prognosis in IgA nephropathy with thrombotic microangiopathy.
Thrombotic microangiopathy (TMA) is a common pathological phenotype of immunoglobulin A nephropathy (IgAN). Low-density granulocytes (LDGs) exhibit potent pro-inflammatory properties and promote neutrophil extracellular trap (NET) formation, playing a pivotal role in thrombus development. This study…
Nanotechnology-mediated podocyte injury repair: mechanistic exploration and therapeutic prospects.
Podocyte injury serves as a central pathological driver in chronic kidney diseases (CKD), including diabetic kidney disease (DKD) and IgA nephropathy (IgAN). However, conventional therapies are still limited by poor targeting efficacy and systemic side effects. Nanotechnology provides transformative…
Research on the safety and efficacy of telitacicept in the treatment of IgA nephropathy in children.
This study retrospectively evaluated telitacicept in ten pediatric IgA nephropathy patients with proteinuria (24-hour urinary protein: 23.97 ± 26.63 mg/kg). All patients received steroid therapy, and half received combined immunosuppressants. After a median follow-up of 3.7…
Clinical significance of serum complement levels and C3/C4 ratio in IgA nephropathy: histopathological correlates and prognostic implications.
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Complement activation plays a central role in its pathogenesis; however, the prognostic significance of serum complement levels remains unclear. In this single-center retrospective study, we evaluated the pr…
Atypical Wiskott-Aldrich syndrome presenting with normal platelet volume and end-stage renal disease: from misdiagnosis as ITP to combined transplantation.
We report a 30-year-old male with a novel WAS mutation (c.252C > A, p.F84L) who was misdiagnosed with immune thrombocytopenia (ITP) for years. Despite persistent thrombocytopenia, his mean platelet volume remained normal, an atypical feature of Wiskott-Aldrich syndrome (WAS). His cours…
The successful use of rituximab in children with IgA nephropathy and minimal change-like lesions: a case series.
IgA nephropathy with minimal change disease (IgAN-MCD) is a rare glomerulopathy combining features of both entities, typically presenting as steroid-sensitive nephrotic syndrome (NS) with frequent relapses. While rituximab (RTX) is commonly used in pediatric glomerular diseases, its efficacy in IgAN…
Regulatory effects of leflunomide on gut microecology during IgA nephropathy treatment.
Growing evidence suggests that the gut-kidney axis may contribute to the pathogenesis of IgA nephropathy (IgAN). However, the effects of immunosuppressants on the intestinal microbiome remain unclear. We investigated how different therapeutic strategies influence gut microbial composition in IgAN pa…
Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease.
In IgA nephropathy (IgAN) with minimal change disease (MCD) (MCD-IgAN), the efficacy of anti-CD20 monoclonal antibodies (mAbs) and the profile of antinephrin antibodies remain poorly understood. We evaluated the efficacy of anti-CD20 mAbs or combined short-course low-dose steroids (anti-CD20 mAbs gr…